PRLISCure's Phase 2 Drug Candidate Granted Orphan Drug Designation (ODD)..
First Orphan Drug Designation (ODD) in the field of microbiome-based treatment for metabolic diseasesSEOUL, South Korea,..2022.12.09
PRLISCure Biosciences Announces Oral Presentation of New Drug Candidate ..
The efficacy and mechanism of NASH microbiome-based therapy for liver fibrosis, steatosis, and inflammation have been co..2022.10.28
PRLISCure Biosciences Announces Research Collaboration with The Scripps ..
SEOUL, South Korea,Feb. 3, 2022/PRNewswire/ --LISCure Biosciences ("LISCure") announced that it had reached an..2022.02.03
PRLISCure Biosciences announces research collaboration with Mayo Clinic ..
SEOUL, South Korea,Jan. 6, 2022/PRNewswire/ -- LISCure Biosciences Inc., a leading biotech focused on microbial-based th..2022.01.06
PRLISCure Biosciences received clinical approval for two microbiome prog..
SEOUL, South Korea,Sept. 30, 2021/PRNewswire/ -- LISCure Biosciences ("LISCure") announced that it has receive..2021.10.01
PRLISCure Biosciences Announces Know-How License Agreement and Stock Pur..
SEOUL, South Korea, Aug. 1, 2021 /PRNewswire/ -- LISCure Biosciences, Inc. ("LISCure") has entered into a kno..2021.08.01
PRLISCure Biosciences Successfully Raises $21 million in Series B Fundin
SEOUL, South Korea,Feb. 26, 2021/PRNewswire/ -- OnFebruary 25th, 2021, LISCure Biosciences Inc., a biotech company that ..2021.02.26
PRLISCure Biosciences Has Completed Seed Funding of USD 5 Million for Ba..
SEOUL, South Korea,July 25, 2019/PRNewswire/ -- LISCure Biosciences, a biotech company that researches and develops bact..2019.07.25